GASTROGRAFIN (diatrizoate meglumine and diatrizoate sodium) by Bracco is clinical pharmacology the most important characteristic of contrast media is the iodine content. First approved in 1958.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
GASTROGRAFIN is an oral and rectal contrast medium containing diatrizoate meglumine and diatrizoate sodium, used for radiographic visualization of the gastrointestinal tract. The iodine content provides radiodensity for contrast imaging, while the high osmolarity produces a mild laxative effect to enhance bowel visualization. It is indicated for diagnostic imaging of the esophagus, stomach, small intestine, and colon.
As a mature legacy diagnostic contrast product approaching loss of exclusivity, the brand team is likely small and focused on maintaining market presence rather than expansion.
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues. Diagnostic enteral radiopaque agents have few known pharmacological…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on GASTROGRAFIN at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Opportunities on GASTROGRAFIN are limited and focused on protecting existing market share and managing decline as the product approaches loss of exclusivity. Career growth on this asset is constrained; positions are more suitable for early-career professionals seeking stable, operational roles or those nearing career transition.